ACG acquires significant stake in Mumbai-based IQGEN-X

The investment aims at augmenting R&D and IP in drug development

ACG offers a wide range of capsules (both gelatin & HPMC)

ACG, a leading supplier of integrated pharmaceutical manufacturing solutions announced acquisition of a significant stake in Mumbai-based start-up IQGEN-X. QIAGEN-X is a Contract Research Organization (CRO) delivering niche and complex drug development technologies for the pharmaceutical industry.

The move sees ACG expanding further into the R&D side of drug development and supports a firm group-wide commitment to improving customer experiences throughout the supply and value chains.

The ACG investment also comes at a critical juncture when the Indian government is at the cusp of announcing a new policy to benchmark the R&D ecosystem by incentivizing innovation and science globally. The funds so infused by ACG will be utilized to set up a cGMP facility and develop and file new Abbreviated New Drug Application (ANDAs).

“IQGENX’s excellent track record in patents and ANDAs speaks for itself, and we look forward to benefitting from its niche technology, broad-based expertise and research specialization that has been recognized globally by WHO and the US FDA,” said Karan Singh, managing director, ACG. “For ACG, this partnership will immediately help expand our group capabilities, and will accelerate our innovation strategy of bold, disciplined investment and world class execution to drive sustainable long-term growth with drug companies in India and global markets.”

Dr Mandar M Kodgule, chairman and chief executive officer, IQGEN-X, commented, “We at IQGEN-X are delighted to have ACG as partner whose strong global footprints and excellent operational capabilities, bring great synergy to IQGEN-X’s growth strategy. ACG’s strategic investment augments our technical expertise, portfolio strategy and corporate vision to create a robust portfolio of limited competition complex products for regulated markets. We believe that this partnership will open several other opportunities which will accelerate growth of both companies.”

IQGENX was established in October 2016 with a vision of innovative research and technology to produce high quality, affordable, safe, and effective medicines. Its state-of-art R&D facility for niche and complex generic products, expertise in technology transfer, regulatory, IP, and compliance enables it to cater to US, European, and other highly regulated markets. Led by healthcare experts and pharmaceutical scientists with over 150 years of combined experience, the company is on the path to growing from a contract research organization (CRO) to a fully integrated pharmaceutical company.

ACG has been providing innovative and integrated solutions to the global pharmaceutical and nutraceutical industries for almost 60 years, in over 100 countries across six continents. ACG products include capsules, film and foil barriers, engineering equipment, and inspection systems. All comply fully with international regulatory requirements.

The Covid-19 pandemic led to the country-wide lockdown on 25 March 2020. It will be two years tomorrow as I write this. What have we learned in this time? Maybe the meaning of resilience since small companies like us have had to rely on our resources and the forbearance of our employees as we have struggled to produce our trade platforms.

The print and packaging industries have been fortunate, although the commercial printing industry is still to recover. We have learned more about the digital transformation that affects commercial printing and packaging. Ultimately digital will help print grow in a country where we are still far behind in our paper and print consumption and where digital is a leapfrog technology that will only increase the demand for print in the foreseeable future.

Web analytics show that we now have readership in North America and Europe amongst the 90 countries where our five platforms reach. Our traffic which more than doubled in 2020, has at times gone up by another 50% in 2021. And advertising which had fallen to pieces in 2020 and 2021, has started its return since January 2022.

As the economy approaches real growth with unevenness and shortages a given, we are looking forward to the PrintPack India exhibition in Greater Noida. We are again appointed to produce the Show Daily on all five days of the show from 26 to 30 May 2022.

It is the right time to support our high-impact reporting and authoritative and technical information with some of the best correspondents in the industry. Readers can power Packaging South Asia’s balanced industry journalism and help sustain us by subscribing.

– Naresh Khanna

Subscribe Now


Please enter your comment!
Please enter your name here